Back

Atrial fibrillation reversal and progression rates: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Outcomes in atrial fibrillation Defining Types of Atrial Fibrillation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Elnaz Shahmohamadi

University of Adelaide, Adelaide (Australia)

6 More presentations in this session

Presentation thumbnail
Regional differences in clinical outcomes in patients of asian race with atrial fibrillation randomized to direct oral anticoagulants vs warfarin: a patient-level meta-analyses from COMBINE AF
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
New-onset atrial fibrillation after multivessel PCI or CABG: a nationwide study
Doctor E. Sunnefeldt (Orebro, SE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and adverse outcomes in newly diagnosed atrial fibrillation: a report from two prospective registries in europe and east-asia
Doctor M. Rossi (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Characteristics and outcomes of young atrial fibrillation patients with a normal heart: insights from a prospective cohort and database analysis
Doctor R. Richard-Vitton (Marseille, FR)
Abstract Slides Video
Presentation thumbnail
Transient new-onset atrial fibrillation after myocardial infarction and adverse outcomes
Doctor M. Fischman (Jerusalem, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Outcomes in atrial fibrillation

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Registries on atrial fibrillation and sudden death
thumbnail
Congress Session
Registries, observational, and other studies on atrial fibrillation
thumbnail
Congress Presentation
Atrial fibrillation progression and healthcare burden: data from the RACE V study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources